Longitude Capital Partners IV, LLC - 07 Nov 2023 Form 4 Insider Report for Lexeo Therapeutics, Inc. (LXEO)

Role
10%+ Owner
Signature
Longitude Capital Partners IV, LLC By: /s/ Cristiana Blauth Oliveira , Authorized Signatory
Issuer symbol
LXEO
Transactions as of
07 Nov 2023
Net transactions value
+$4,999,995
Form type
4
Filing time
09 Nov 2023, 20:32:53 UTC
Previous filing
02 Nov 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LXEO Common Stock Conversion of derivative security +1,793,429 1,793,429 07 Nov 2023 By Longitude Venture Partners IV, L.P. F1, F2
transaction LXEO Common Stock Conversion of derivative security +319,126 +18% 2,112,555 07 Nov 2023 By Longitude Venture Partners IV, L.P. F2, F3
transaction LXEO Common Stock Purchase $4,999,995 +454,545 +22% $11.00* 2,567,100 07 Nov 2023 By Longitude Venture Partners IV, L.P. F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LXEO Series A convertible preferred stock Conversion of derivative security -18,999,999 -100% 0 07 Nov 2023 Common Stock 1,793,429 By Longitude Venture Partners IV, L.P. F1, F2
transaction LXEO Series B convertible preferred stock Conversion of derivative security -2,906,148 -100% 0 07 Nov 2023 Common Stock 319,126 By Longitude Venture Partners IV, L.P. F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Upon the closing of the Issuer's initial public offering, each share of Series A convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-10.594230 basis. The shares had no expiration date.
F2 These shares are held by Longitude Venture Partners IV, L.P ("LVP IV"). Longitude Capital Partners IV, LLC ("LCP IV") is the general partner of LVP IV and may be deemed to have voting and dispositive power over the shares held by LVP IV. Mr. Enright and Ms. Tammenoms Bakker are managing members of LCP IV and may be deemed to share voting and dispositive power with respect to the shares held by LVP IV. Each of LCP IV, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
F3 Upon the closing of the Issuer's initial public offering, each share of Series B convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-9.106601 basis, which reflects an anti-dilution adjustment to the conversion ratio pursuant to a provision of the Series B convertible preferred stock based on the pricing of the initial public offering (as described in the Reporting Person's Form 3). The shares had no expiration date.